Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tedizolid, Dalbavancin Still Face Questions On ABSSSI Lesion Measurement

Apr 07 2014

• By Derrick Gingery

Related Content

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

Sep 06 2010

FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says

Sep 13 2010

Related Companies

Cubist Pharmaceuticals, Inc.

Forest Laboratories, Inc.

Trius Therapeutics, Inc.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window